CoChat

BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature

Open access
Guerrero, Patricia, Albarrán, Víctor, San Román, María, González-Merino, Carlos, García de Quevedo, Coral, Moreno, Jaime, Calvo, Juan Carlos, González, Guillermo, Orejana, Inmaculada, Chamorro, Jesús, Martínez-Delfrade, Íñigo, Morón, Blanca, de Frutos, Belén, Ferreiro, María Reyes · 2023 · Cancers

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Abstract

Metastatic colorectal cancer (mCRC) with mutated BRAF exhibits distinct biological and molecular features that set it apart from other subtypes of CRC. Current standard treatment for these tumors involves a combination of chemotherapy (CT) and VEGF inhibitors. Recently, targeted therapy against BRAF and immunotherapy (IT) for cases with microsatellite instability (MSI) have been integrated into clinical practice. While targeted therapy has shown promising results, resistance to treatment eventually develops in a significant portion of responsive patients. This article aims to review the available literature on mechanisms of resistance to BRAF inhibitors (BRAFis) and potential therapeutic strategies to overcome them.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers15215243

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 MAPK and PI3K/AKT/mTOR pathway.
Figure 1 MAPK and PI3K/AKT/mTOR pathway.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Cited by

See all 26

Metadata

Authors
Guerrero, P., Albarrán, V., San Román, M., González-Merino, C., García de Quevedo, C., Moreno, J., Calvo, J. C., González, G., Orejana, I., Chamorro, J., Martínez-Delfrade, Í., Morón, B., de Frutos, B., & Ferreiro, M. R.
Affiliations
  • Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain
  • Hospital Universitario Ramón y Cajal (ES)
Venue
Cancers
Publisher
MDPI AG
Published
2023-10-31
Volume
15
Issue
21
Pages
5243
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4388041706
Cited by
21
References
74
Citations by year
2026: 6 · 2025: 8 · 2024: 7
FWCI
0.68
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
BRAF inhibitors, metastatic colorectal cancer, BRAF mutation, drug resistance mechanisms, VEGF inhibitors, chemotherapy, immunotherapy, microsatellite instability, targeted therapy, resistance reversal strategies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature. https://app.cochat.ai/papers/10.3390/cancers15215243
The paper
Guerrero, P., Albarrán, V., San Román, M., González-Merino, C., García de Quevedo, C., Moreno, J., Calvo, J. C., González, G., Orejana, I., Chamorro, J., Martínez-Delfrade, Í., Morón, B., de Frutos, B., & Ferreiro, M. R. (2023). BRAF Inhibitors in Metastatic Colorectal Cancer and Mechanisms of Resistance: A Review of the Literature. Cancers. https://doi.org/10.3390/cancers15215243

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.